EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn’s Disease: A Post Hoc Analysis of 3 Phase 3 Trials

Jean-Frédéric Colombel, Ana P Lacerda, Peter M Irving, Remo Panaccione, Walter Reinisch, Florian Rieder, Adam Steinlauf, David Schwartz, Tian Feng, Elena Dubcenco, Samuel I Anyanwu, F Stephen Laroux und 2 weitere

Clinical Gastroenterology and Hepatology · 2025-05 · 23 (6) · 1019-1029

DOI: 10.1016/j.cgh.2024.08.032 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025-05. Verfasst von Jean-Frédéric Colombel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic addre…. Hauptthemen laut MEDLINE: Crohn Disease, Heterocyclic Compounds, 3-Ring, Rectal Fistula, Janus Kinase Inhibitors. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseHeterocyclic Compounds, 3-RingRectal FistulaJanus Kinase InhibitorsHumansMaleFemaleAdultTreatment OutcomeMiddle AgedYoung AdultPlacebosAdolescentDouble-Blind Method

Stichwörter der Autor:innen

Crohn’s DiseaseFistulaJAK InhibitorPerianalUpadacitinib

Substanzen

Heterocyclic Compounds, 3-RingupadacitinibPlacebosJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: jean-frederic.colombel@mssm.edu.
  • AbbVie Inc., North Chicago, Illinois.
  • IBD Centre, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada.
  • Department of Internal Medicine, Medical University of Vienna, Vienna, Austria.
  • Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases Institute, Cleveland Clinic, Cleveland, Ohio.

Förderung

  • AbbVie Inc

Zitieren

APA

Colombel, J. F., Lacerda, A. P., Irving, P. M., Panaccione, R., Reinisch, W., Rieder, F., Steinlauf, A., Schwartz, D., Feng, T., Dubcenco, E., Anyanwu, S. I., Laroux, F. S., Cunneen, C., & Powell, N. (2025). Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn’s Disease: A Post Hoc Analysis of 3 Phase 3 Trials. Clinical Gastroenterology and Hepatology, 23(6), 1019-1029. https://doi.org/10.1016/j.cgh.2024.08.032

Vancouver

Colombel JF, Lacerda AP, Irving PM, Panaccione R, Reinisch W, Rieder F, et al. Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn’s Disease: A Post Hoc Analysis of 3 Phase 3 Trials. Clinical Gastroenterology and Hepatology. 2025;23(6):1019-1029. doi:10.1016/j.cgh.2024.08.032

BibTeX
@article{Colombel2025,
  author = {Colombel, Jean-Frédéric and Lacerda, Ana P and Irving, Peter M and Panaccione, Remo and Reinisch, Walter and Rieder, Florian and Steinlauf, Adam and Schwartz, David and Feng, Tian and Dubcenco, Elena and Anyanwu, Samuel I and Laroux, F Stephen and Cunneen, Colla and Powell, Nick},
  title = {Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn’s Disease: A Post Hoc Analysis of 3 Phase 3 Trials},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2025},
  volume = {23},
  number = {6},
  pages = {1019--1029},
  doi = {10.1016/j.cgh.2024.08.032}
}
Kostenlos starten →